Member Info for Scinv_temp

 (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world's first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust. The results from this landmark study, show that a SARS-CoV-2 human challenge is safe in healthy young adults and provide detailed insights into the course of COVID-19 infection with potential positive public health implications.

As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that caused a safe and reliable infection in unvaccinated volunteers with no prior SARS-CoV-2 infection. The results published today detail the outcome of the 36 healthy male and female volunteers aged 18-29 years which were infected with the original SARS-CoV-2 strain challenge virus. hVIVO clinicians closely monitored volunteers in a controlled quarantined setting and collected disease progression data to provide insights into COVID-19 infection. Volunteers will be followed up for 12 months after discharge from the quarantine facility.

The key clinical insights were as follows:

Viral load ("VL")

·    18 volunteers (50%) became infected with viral load (VL) rising steeply and peaking at ~five days post-inoculation

·    No quantitative correlation was noted between VL and symptoms

Symptoms

·   No serious symptoms

·   Mild-to-moderate cold like symptoms were reported by 16 (88%) of 18 infected volunteers including a stuffy or runny nose, sneezing, and a sore throat. Some experienced headaches, muscle/joint aches, tiredness and fever

·    Anosmia (lost or changed sense of smell) occurred in 13 (72% of infected) volunteers

Virus detection

·    Average time from first exposure to viral detection and early symptoms (incubation period) was 42 hours

·    Virus was detected earliest in the throat but at significantly greater levels in the nose;

o  Virus detected in the throat on average after 40 hours

o  Virus detected in the nose on average after 58 hours

·    High levels of viable (infectious) virus was seen for approximately nine days post-inoculation, and up to a maximum of 12 days

·    Modelling using the study data indicated that regular asymptomatic lateral flow testing ("LFT") would diagnose infection before 70-80% of infectious virus had been generated, thus if isolation was triggered would decrease community transmission to others

Importantly, no serious adverse events (SAEs) occurred, and the SARS-CoV-2 human challenge study model was shown to be safe and well tolerated in healthy young adults. With the characterisation study disease modelling data completed, and a COVID-19 Human Challenge Model now established, the Compan

Thanks for this. Data looks good, up to health authorities now to support expansion and further development, it'd be crazy not to imho.

Hahahahahahahaahah

That's all fantastic and evident since the copd results and pointed out since last year. The problem is sng is doing none of those things and they are basically just going for it the same way they always did. If you heard variations of the phrase "not enough exacerbations" and "improvement in breathlessness" for the first time during covid then you haven't actually studied sng. They couldn't even bother to do in vitro with their own virus and against variants, they presented someone else's data instead and ones that involve pretreatment which has nothing to do with hospitalised patients that they chose to focus on.

Well, technically, they need a stockpile to get the EUA but usually this means to apply as well.

To apply for EUA they also need a stockpile and the company said EUA is not in their plans.

Governments will open the doors to their vaults for RM to inspect their worth, women screaming for just a look from him, tattoo shops competing for the best stylised "RM" tattoo, and so on and so forth...

Can you imagine if it was around during this pandemic?

(Couldn't help it)

Andrew yes I've misread your comment, but then again I've been trying to convince the gang here since last year that this is the case. Glad to see it is the case :)

That is what RM said. Yes :)

Andrew so is the answer to the question
"Is it a fact that anyone that makes and sells an inhaled ifn b for covid needs a license from synairgen"

A yes?

And I'm not making stuff up, one the criteria for progressing to phase 3 is to be convinced that the company can supply quantities, yes they do as for information from the start but the also want to see progress. Look at it from another perspective that you'd probably like better, if they do progress to pahse 3 on activ 2, apart from the clinical part it would mean activ people were satisfied with progress on manufacturing as well.

Depends on what you define as issue. Still haven't answered if you think it is a fact no one else can make and sell an inhaled ifn b treatment unless they license from synairgen.

Poor planning wasn't their fault and the activ inclusion wasn't something they were trying to do from before, they just sent a letter beg him to take part at the last minute. Sure

Which is why I still hold a small number of shares just in case they progress them to phase 3 on activ 2 and get their own phase 3 done, though the company seems to be downplaying the activ 2 path and that matters for progression to the next phase on activ. Then again it impossible to tell what RM is saying to whom.

Matterhorn, this was mentioned in official recovery documents earlier though it was mostly that they didn't believe they could scale up to supply the market mostly and also specifically in the activ documents that they did not have as much as they wanted to for the trials. PERIOD.

Ghia perhaps they'll give them a pity patent. Lol.
It was their choice to do what they did (which was valued at 225M + royalties) and also their idea to pretend during covid that all of a sudden this is entirely novel and let people believe that valuations in the billions were all of a sudden normal. Their delusion that they would sell this for a huge number of people at £2.5K and in fact they couldn't even sort out manufacturing for the trials. Actually, it was their lie, the delusion is yours.

*Sarscov2

And how come I'm the one with the agenda while it is you spreading misinformation?

But they were not even the first to have the idea to treat sarscoc2 or ANY virus with ANY ifn or using an inhaled version to do it. NONE of that was their idea.

No man. It you hasn't got a clue how patents work.